NASDAQ$VTYX
Ventyx Biosciences Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Ventyx Biosciences reported its second quarter 2025 financial results, highlighting progress in its clinical pipeline and maintaining a strong cash position.
Ventyx Biosciences reported a net loss of $27.0 million for Q2 2025, an improvement from $32.0 million in Q2 2024. The company's R&D and G&A expenses both decreased, contributing to a lower total operating loss. Ventyx maintains a strong cash position of $209.0 million, expected to fund operations into at least H2 2026, and has made significant progress in its Phase 2 clinical trials for VTX3232 and VTX2735.
- Net loss improved to $27.0 million in Q2 2025 from $32.0 million in Q2 2024.
- Research and Development (R&D) expenses decreased to $22.3 million, down from $27.8 million in the prior year quarter.
- General and Administrative (G&A) expenses also saw a reduction, falling to $7.1 million from $7.9 million.
- The company's cash, cash equivalents, and marketable securities stood at $209.0 million as of June 30, 2025, providing funding into at least H2 2026.
Headline financials
Revenue & EPS history
Ventyx Biosciences · Revenue · Quarterly
$0
Forward guidance
Ventyx Biosciences anticipates significant clinical milestones in Q4 2025, with topline data expected from Phase 2 studies of VTX2735 in recurrent pericarditis and VTX3232 in cardiometabolic diseases. The company's current cash position is projected to fund operations into at least the second half of 2026.
Tailwinds
- Topline data from the Phase 2 study of VTX2735 in recurrent pericarditis expected in Q4 2025.
- Topline data from the Phase 2 study of VTX3232 in participants with obesity and cardiometabolic risk factors expected in early Q4 2025.
- Cash, cash equivalents, and marketable securities of $209.0 million are expected to fund planned operations into at least H2 2026.
- Positive topline Phase 2a biomarker data for VTX3232 position it as a potential disease-modifying therapy for Parkinson’s disease.
- Planning discussions initiated for a placebo-controlled, Phase 2 trial of VTX3232 in Parkinson’s disease and potentially other neurodegenerative disorders.
Headwinds
- Potential delays in the commencement, enrollment, and completion of clinical trials.
- Dependence on third parties for product manufacturing, research, and preclinical/clinical testing.
- Disruptions in the supply chain, including raw materials and animals used in research.
- Early clinical trials not necessarily being predictive of future results, and interim results not necessarily being predictive of final results.
- Unexpected adverse side effects or inadequate efficacy of product candidates that may limit development, regulatory approval, and/or commercialization.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 8 quarterly earnings reports · overlaid with Q2 2025
+4.2%
Avg return
Earnings day
+7.1%
Avg return
5 days after
+13.8%
Avg return
30 days after
56%
10 / 18 earnings
Positive
+34.4%
Q2 2022
Best reaction
-11.9%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -5.7% | +2.5% | -6.0% | |
| Q2 2025 | +18.4% | +20.5% | +6.8% | |
| Q1 2025 | +7.0% | +1.8% | +113.2% | |
| Q4 2024 | +9.0% | +4.2% | -16.1% | |
| Q3 2024 | -5.6% | -10.0% | +34.2% | |
| Q2 2024 | +5.6% | -0.5% | +10.9% | |
| Q1 2024 | -7.9% | -6.3% | -26.4% | |
| Q4 2023 | +32.6% | +45.0% | -6.5% | |
| Q3 2023 | -11.9% | — | — | |
| Q2 2023 | +1.9% | — | — | |
| Q1 2023 | -11.6% | — | — | |
| Q4 2022 | -8.3% | — | — | |
| Q3 2022 | -9.1% | — | — | |
| Q2 2022 | +34.4% | — | — | |
| Q1 2022 | +10.6% | — | — | |
| Q2 2021 | +9.3% | — | — | |
| Q4 2021 | +9.3% | — | — | |
| Q3 2021 | -1.7% | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro